Salute e Benessere
The Global Anti-Inflammatory Therapeutics Market Forecast 2017-2027
Anti-Inflammatory Therapeutics
Where is the Anti-Inflammatory Therapeutics market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Our 162-page report provides 108 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Anti-Inflammatory Therapeutics market. See how to exploit the opportunities.
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Along with revenue prediction for the overall world market, there are forecasts for 5 Indications and 4 Drug Classes
• Arthritis
• Respiratory Conditions
• Multiple Sclerosis
• Inflammatory Bowel Diseases
• Other
• Corticosteroids
• Anti-Inflammatory Biologics
• NSAIDs
• Other Anti-Inflammatory Therapeutics
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 11 leading national markets:
• The US
• Canada
• Germany
• France
• The UK
• Italy
• Spain
• Japan
• China
• India
• Russia
• Brazil
The report also includes profiles and forecasts for some of the leading companies in the Anti-Inflammatory Therapeutics market, with a focus on the Anti-Inflammatory Therapeutics segment of these companies' operations.
There will be growth in both established and in developing countries. Our analyses show that the developing markets, China in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.
Overall world revenue for Anti-Inflammatory Therapeutics will surpass
$75bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of autoimmune disease, and increasing ageing population will increase sales to 2027.
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 162-page report provides you with the following knowledge:
- discover the industry's prospects, finding the most lucrative places for investments and revenues
- US,
Germany , UK, France ,
Italy , Spain ,
Japan , China ,
Brazil , Russia ,
India
- including company profiles and forecasts for 8 companies' anti-inflammatory segment revenues to 2027
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the Anti-Inflammatory Therapeutics market and leading companies. You will find data, trends and predictions.
Get our report today The Global Anti-Inflammatory Therapeutics Market Forecast 2017-2027 . Avoid missing out - get our report now.
To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100
Or click on https://www.visiongain.com/Report/1901/The-Global-Anti-Inflammatory-Therapeutics-Market-Forecast-2017-2027
Abbott Laboratories
AbbVie
Ablynx NV
Alcon
Alder Biopharmaceuticals
Amgen
Amylin
Anacor
Ardea Biosciences
Astellas Pharma
Avid Radiopharmaceuticals
Baxalta
Biocad
Biocon
Biogen
BioXpress Therapeutics
Boehringer Ingelheim
Bristol- Myers Squibb (BMS)
Can-Fite BioPharma
Celltrion Inc
Chiron
Chugai
Cipla
Coherus BioSciences
Covagen
Cubist
Daiichi Sankyo
Depuy
Dr. Reddy's Laboratories
Eli Lilly & Company
Epirus Biopharmaceuticals
Fremont
Fujifilm Corporation
Galapagos NV
Genentech
Gilead Sciences
GlaxoSmithKline
Hanmi Pharmaceutical Co
Hanwha Biologics
Hetero Healthcare
Hospira
Idenix
ImClone Systems
Immunex
Incyte Corporation
Intas Pharmaceuticals
Janssen
Johnson & Johnson
Kyowa Hakko Kirin Co
LG Life Sciences
MedImmune
Medivation
Merck
Mitsubishi Tanabe Pharma Corporation
Momenta Pharmaceuticals
MorphoSys
Mycenax Biotech
Mylan
Nichi-Iko Pharmaceutical Co
Novartis
Onyx
Pfizer
Pharmacyclics
Protalix Biotherapeutics
Roche
Roche Diagnostics
Samsung Bioepis Co
Samsung BioLogics
Sandoz
Sanofi
Shanghai Celgen Bio-Pharmaceutical Co
Shanghai CP Guojian Pharmaceutical Co
Sima Therapeutics
Simcere Pharmaceutical Group
Stiefel
Sun Pharmaceutical Industries
Takeda
Tempero
UCB
Vitaeris
Zydus Cadila
To see a report overview please email Sara Peerun on sara.peerun@visiongain.com